Skip to main content
Press

United Biosource Corporation (UBC) Receives High Marks for Staff Quality According to ISR Report

By December 20th, 2021No Comments

Informing the pharmaceutical drug development and commercialization industry.

Cary, N.C. – January 6, 2013 – Industry Standard Research (ISR) has announced the availability of a new report titled “2013 CRO Quality Benchmarking – Phase IV Service Providers.”  This study surveyed 106 pharmaceutical and biotechnology professionals about their experiences with 27 small, mid-size, and large Phase IV CROs.  Together, these responses provide insight into 208 unique service encounters.

“According to the respondents, UBC’s ‘project manager quality’ and ‘therapeutic expertise’ were two of the seven staff characteristics that set their staff apart and earned them this top rank as industry leaders,” explained Kevin Olson, CEO of Industry Standard Research.  “When it comes to global, logistically challenging studies,” Olson continued, “an aspect that sponsors indicate is growing in importance is the ‘local market / regulatory knowledge’.  The respondents have indicated that Quintiles has a strong grasp of this area.”

Respondents rated 27 CROs across 26 different staff, operational, and organizational service quality attributes.  These include: Overall Value, Low Cost, and Prior Positive Experience with Service Provider, among others.  The 27 Phase IV CROs included in this report are: Accelovance, Aptiv Solutions, BioClinica, Charles River Laboratories, Chiltern, Cognizant, Covance, DaVita Clinical Research, DCRI – Duke, Eurofins, ICON, INC Research, inVentiv Health Clinical, Medpace, Novella, PAREXEL, PPD, PRA, Premier Research, Quintiles, Mapi, RPS, SGS, Tata, Theorem, UBC, and Worldwide Clinical Trials.

“This report has two simple missions: help sponsor companies make more informed CRO selection decisions and help service providers optimize their operational and marketing strategies.  The 208 unique service encounters provide a valuable tool that will help sponsor/ CRO relationships run as effectively and as efficiently as possible,” stated Olson.

For more information on ISR’s “2013 CRO Quality Benchmarking – Phase IV Service Providers” report, please visit ISR’s report page at https://isrreports.com/product/2013-cro-quality-benchmarking-phase-iv-service-providers/

For more information on ISR’s Phase I and Phase II/III CRO Quality Benchmarking reports, you can visit ISR’s Web site at https://isrreports.com/product-category/cro-and-service-provider-benchmarking-reports/

About Industry Standard Research

Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries.  With over a decade of experience, ISR delivers an unmatched level of domain expertise.  For more information about our off-the-shelf intelligence and custom research offerings, please visit the company’s Web site at www.ISRreports.com, email info@ISRreports.com, or follow us on Twitter @ISRreports.